Substance injected | Preinjection | First injection | Second injection | |
---|---|---|---|---|
sec | ||||
Saline/saline | °C | 22.77 ± 0.05 | 24.38 ± 0.25 | 22.77 ± 0.03 |
Latency | 3.43 ± 0.15 | 3.02 ± 0.15 | 3.45 ± 0.24 | |
DMSO/DMSO | °C | 26.1 ± 0.16 | 28.97 ± 0.80 | 26.33 ± 0.20 |
Latency | 3.32 ± 0.11 | 2.77 ± 0.25 | 3.37 ± 0.13 | |
SR 48692/saline1-a | °C | 22.90 ± 0.26 | 26.30 ± 0.75 | 23.78 ± 0.19 |
Latency | 3.23 ± 0.13 | 2.55 ± 0.22 | 3.18 ± 0.13 | |
Neurotensin1-b | °C | 24.63 ± 0.11 | 28.63 ± 1.25 | N.D. |
Latency | 3.18 ± 0.15 | 4.47 ± 0.90 | N.D. |
↵1-a SR 48692 dose was 0.03 pmol, a dose that did not subsequently cause an increase in TFL (fig. 1); the second injection was performed with saline.
↵1-b Neurotensin dose was 10 nmol, a dose that is antinociceptive, thus accounting for the rise in TFL, even though tail temperature is increased. A second injection was not administered in this experimental group (N.D.).